Verfügbarkeit: Practical handbook of brachytherapy | Technische Universität München

Practical handbook of brachytherapy:

Gespeichert in:

Bibliographische Detailangaben
Beteiligte Personen:	Strnad, Vratislav (VerfasserIn, HerausgeberIn), Niehoff, Peter 1967- (VerfasserIn, HerausgeberIn), Lößl, Kristina 1967- (VerfasserIn, HerausgeberIn), Kirisits, Christian (VerfasserIn, HerausgeberIn)
Format:	Buch
Sprache:	Englisch
Veröffentlicht:	Bremen ; London ; Boston UNI-MED Verlag AG [2023]
Ausgabe:	2nd edition
Schriftenreihe:	UNI-MED SCIENCE
Schlagwörter:	Brachytherapie Aufsatzsammlung
Links:	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034354136&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
Umfang:	286 Seiten Illustrationen, Diagramme 25 cm, 678 g
ISBN:	9783837416473 383741647X

Internformat

MARC


LEADER	00000nam a2200000 c 4500
001	BV049092439
003	DE-604
005	20240215
007	t\|
008	230807s2023 gw a\|\|\| \|\|\|\| 00\|\|\| eng d
015			\|a 23,N10 \|2 dnb
015			\|a 23,A19 \|2 dnb
016	7		\|a 1281984809 \|2 DE-101
020			\|a 9783837416473 \|c Festeinband : EUR 69.80 (DE), EUR 71.80 (AT), CHF 74.80 (freier Preis) \|9 978-3-8374-1647-3
020			\|a 383741647X \|9 3-8374-1647-X
024	3		\|a 9783837416473
035			\|a (OCoLC)1371482539
035			\|a (DE-599)DNB1281984809
040			\|a DE-604 \|b ger \|e rda
041	0		\|a eng
044			\|a gw \|c XA-DE-HB
049			\|a DE-578 \|a DE-355
082	0	4	\|a 615.842 \|2 23/ger
084			\|a YR 3303 \|0 (DE-625)154103:12909 \|2 rvk
084			\|8 1\p \|a 610 \|2 23sdnb
084			\|a WN 250.5.B7 \|2 nlm
245	1	0	\|a Practical handbook of brachytherapy \|c Vratislav Strnad, Peter Niehoff, Kristina Lössl, Christian Kirisits ; in collaboration with Stefanie Corradini [und 20 weiteren]
250			\|a 2nd edition
264		1	\|a Bremen ; London ; Boston \|b UNI-MED Verlag AG \|c [2023]
264		4	\|c © 2023
300			\|a 286 Seiten \|b Illustrationen, Diagramme \|c 25 cm, 678 g
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
490	0		\|a UNI-MED SCIENCE
650	0	7	\|a Brachytherapie \|0 (DE-588)4219194-4 \|2 gnd \|9 rswk-swf
655		7	\|0 (DE-588)4143413-4 \|a Aufsatzsammlung \|2 gnd-content
689	0	0	\|a Brachytherapie \|0 (DE-588)4219194-4 \|D s
689	0		\|5 DE-604
700	1		\|a Strnad, Vratislav \|0 (DE-588)1146611870 \|4 edt \|4 aut
700	1		\|a Niehoff, Peter \|d 1967- \|0 (DE-588)120743051 \|4 edt \|4 aut
700	1		\|a Lößl, Kristina \|d 1967- \|0 (DE-588)124526276 \|4 edt \|4 aut
700	1		\|a Kirisits, Christian \|4 edt \|4 aut
710	2		\|a UNI-MED Verlag AG \|0 (DE-588)1065561733 \|4 pbl
780	0	0	\|i Vorangegangen ist \|z 9783837414493
856	4	2	\|m DNB Datenaustausch \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034354136&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
883	2		\|8 1\p \|a dnb \|d 20230504 \|q DE-101 \|u https://d-nb.info/provenance/plan#dnb
943	1		\|a oai:aleph.bib-bvb.de:BVB01-034354136

Datensatz im Suchindex

_version_	1819306049568505856
adam_text	CONTENTS 11 CONTENTS INTRODUCTION 21 HISTORY OF BRACHYTHERAPY 22 YY PHYSICAL ASPECTS - SOURCES, DOSIMETRY AND DOSE SPECIFICATION 28 3.1. SOURCES ...................................................................................................................................................... 28 3.1.1. RADIONUCLIDES IN BRACHYTHERAPY ............................................................................................................. 28 3.1.1.1. GAMMA AND CHARACTERISTIC X-RAY RADIATION .................................................................................................. 28 3.1.1.2. BETA-EMITTERS ............................................................................................................................................... 29 3.1.2. CHARACTERISATION OF SOURCE STRENGTH ........................................................................................................ 29 3.2. DOSIMETRY ................................................................................................................................................. 29 3.2.1. CONTROL OF REFERENCE AIR KERMA RATE .......................................................................................................... 29 3.2.1.1. MEASUREMENT WITH WELL-TYPE IONISATION CHAMBERS ..................................................................................... 29 3.2.1.2. MEASUREMENT IN COMPACT CHAMBERS IN SOLID BODY PHANTOMS ................................................................... 29 3.2.2. CHECKING THE SOURCE POSITION .................................................................................................................. 30 3.2.3. CALCULATION OF DOSE DISTRIBUTIONS ............................................................................................................. 30 3.2.3.1. DOSE DISTRIBUTIONS OF SINGLE SOURCES............................................................................................................ 30 3.2.3.2. APPLICATOR RECONSTRUCTION ............................................................................................................................ 31 3.2.4. OPTIMISATION AND VISUALISATION OF DOSE DISTRIBUTIONS ............................................................................ 33 YY QUALITY ASSURANCE 38 4.1. QUALITY ASSURANCE FOR AFTERLOADING DEVICES AND PROCEDURES IN CASE OF EMERGENCY FOR A REMOTE AFTERLOADER ............................................................................................................... 38 4.2. QUALITY ASSURANCE IN BRACHYTHERAPY TREATMENT PLANNING SYSTEMS .............................................. 41 4.3. SPECIAL METHODS ................................................................................................................................... 41 DOSIMETRICAL ASPECTS - DOSE SPECIFICATIONS, DOSE-VOLUME DEFINITIONS, EQD2 CONCEPT 46 5.1. DOSE SPECIFICATION IN GENERAL ................................................................................................................ 46 5.2. DOSE SPECIFICATION IN INTRALUMINAL AND INTRACAVITARY THERAPY ............................................................... 47 5.2.1. SOURCE POSITIONS ALONG ONE STRAIGHT LINE (E.G. VAGINAL CYLINDER, OESOPHAGEAL/BRONCHIAL APPLICATORS, VESSELS) ............................................................................................................... 47 5.2.2. ADVANCED CERVICAL CARCINOMA .................................................................................................................. 48 5.2.3. ENDOMETRIAL CARCINOMA NOT TREATED SURGICALLY ....................................................................................... 48 5.3. DOSE SPECIFICATION IN INTERSTITIAL BRACHYTHERAPY ............................................................................... 48 5.3.1. POINT BASED SYSTEMS .................................................................................................................................. 48 5.3.2. DOSE AND VOLUME RELATIONS, DOSE-VOLUME HISTOGRAMS (DVH) AND QUALITY PARAMETERS (INDICES) .... 50 5.3.2.1 . RELEVANT DOSE VALUES AND VOLUMES ............................................................................................................. 50 5.3.2.2. QUALITY PARAMETERS - QI INDICES .................................................................................................................. 51 5.4. DOSE FRACTIONATION, COMBINATION WITH EXTERNAL BEAM AND THE EQD2 CONCEPT .............................. 53 YY CLINICAL TREATMENT PLANNING AND IMAGING 56 6.1. CLINICAL TREATMENT PLANNING ................................................................................................................. 56 6.1.1. INDICATION ................................................................................................................................................... 56 6.1.1.1. DEFINITIVE TREATMENT ................................................................................................................................... 56 6.1.1.2. ADJUVANT THERAPY ........................................................................................................................................ 56 12 CONTENTS 6.1.2. GROSS TARGET VOLUME (GTV) AND CLINICAL TARGET VOLUME (CTV) ............................................................. 56 6.1.3. SELECTION OF TECHNIQUE, PRELIMINARY AND DEFINITIVE TREATMENT PLAN ...................................................... 57 6.1.3.1. INTERSTITIAL BRACHYTHERAPY ............................................................................................................................ 57 6.1.3.2. INTRACAVITARY BRACHYTHERAPY ......................................................................................................................... 60 6.1.3.3. INTRALUMINAL BRACHYTHERAPY ......................................................................................................................... 60 6.1.4. DOSE, DOSE FRACTIONATION, DOSE RATE .......................................................................................................... 60 6.1.5. INFRASTRUCTURE AND PERSONNEL PLANNING ................................................................................................... 61 6.2. MODERN IMAGING TECHNIQUES IN BRACHYTHERAPY ................................................................................. 62 6.2.1. BASICS OF IMAGE-GUIDED BRACHYTHERAPY ................................................................................................... 62 6.2.2. IMAGE-GUIDED PRELIMINARY TREATMENT PLANNING ...................................................................................... 64 6.2.3. IMAGE-GUIDED APPLICATION ........................................................................................................................ 64 6.2.4. IMAGE-GUIDED DEFINITIVE TREATMENT PLANNING ......................................................................................... 65 6.2.5. IMAGING TECHNIQUES IN BRACHYTHERAPY ..................................................................................................... 66 6.2.5.1. CT IMAGING ................................................................................................................................................... 66 6.2.5.2. MR IMAGING .................................................................................................................................................. 67 6.2.5.3. US IMAGING ................................................................................................................................................... 67 YY INSTRUMENTS AND EQUIPMENT 69 7.1. INSTRUMENTS FOR INTERSTITIAL BRACHYTHERAPY ........................................................................................... 69 7.1.1. TEMPORARY IMPLANTS .................................................................................................................................. 69 7.1.1.1. NEEDLES, CATHETERS .................................................. 69 7.1.1.2. TEMPLATES ..................................................................................................................................................... 71 7.1.1.3. AUXILIARY INSTRUMENTS ................................................................................................................................... 73 7.1.2. PERMANENT IMPLANTS ................................................................................................................................... 74 7.2. INSTRUMENTS FOR INTRACAVITARY BRACHYTHERAPY ..................................................................................... 75 7.2.1. UTEROVAGINAL APPLICATORS .......................................................................................................................... 75 7.2.2. VAGINAL APPLICATORS .................................................................................................................................... 76 7.2.3. ENDOMETRIAL APPLICATORS ............................................................................................................................ 77 7.2.4. INTRALUMINAL APPLICATORS FOR TUMOURS IN THE OESOPHAGUS, BRONCHUS, TRACHEA, COMMON BILE DUCT AND NASOPHARYNX AND FOR INTRAVASCULAR BRACHYTHERAPY ........................................................................ 77 7.2.5. MOULDS FOR CANCERS OF THE PARANASAL SINUSES OR ORBIT ............................................................................ 78 7.3. SURFACE APPLICATORS .................................................................................................................................. 78 7.3.1. SKIN APPLICATORS ......................................................................................................................................... 78 7.3.2. EYE APPLICATORS .......................................................................................................................................... 79 7.4. AFTERLOADING DEVICES ............................................................................................................................... 79 7.4.1. THE IRRADIATION DEVICE .............................................................................................................................. 80 7.4.2. THE CONTROL UNIT ........................................................................................................................................ 81 7.4.3. IMPORTANT REQUIREMENTS FOR RADIATION PROTECTION .................................................................................. 81 YY INTRA AND PERIOPERATIVE BRACHYTHERAPY 82 8.1. INTRODUCTION ............................................................................................................................................. 82 8.2. INDICATIONS AND PATIENT SELECTION CRITERIA ............................................................................................ 83 8.2.1. INTRAOPERATIVE BRACHYTHERAPY .................................................................................................................. 83 8.2.2. PERIOPERATIVE BRACHYTHERAPY .................................................................................................................... 84 8.3. PRACTICAL EXECUTION AND TECHNIQUE, PRACTICAL TIPS ............................................................................. 85 8.4. TREATMENT PLANNING ................................................................................................................................ 87 8.4.1. TARGET VOLUMES, DOSE SPECIFICATION AND DOSE, QA .................................................................................. 87 8.5. RESULTS ....................................................................................................................................................... 88 CONTENTS 13 8.6. SIDE EFFECTS ............................................................................................................................................... 89 8.6.1. SHORT-TERM TOXICITY ....................................................................................................................................89 8.6.2. LONG-TERM TOXICITY .................................................................................................................................... 89 8.7. SUMMARY ................................................................................................................................................... 90 B INTERSTITIAL HYPERTHERMIA 91 9.1. TECHNIQUES OF INTERSTITIAL HYPERTHERMIA .............................................................................................. 91 9.2. PLANNING, PERFORMANCE AND DOCUMENTATION OF INTERSTITIAL HYPERTHERMIA .................................... 91 9.3. QUALITY AND EFFECTIVENESS OF HYPERTHERMIA ........................................................................................ 92 9.4. TREATMENT RESULTS IN INTERSTITIAL BRACHYTHERAPY AND HYPERTHERMIA ................................................. 92 9.4.1. GLIOBLASTOMA .............................................................................................................................................. 92 9.4.2. LOCAL AND LOCOREGIONAL RECURRENCES OF HEAD AND NECK CANCER ............................................................. 93 9.4.3. BREAST CANCER .............................................................................................................................................. 94 9.4.4. TUMOURS OF THE SMALL PELVIS ...................................................................................................................... 94 9.4.5. PROSTATE CANCER ........................................................................................................................................... 94 9.6. SUMMARY ................................................................................................................................................... 95 YY PRE AND POSTOPERATIVE SUPPORTIVE CARE IN BRACHYTHERAPY 97 10.1. PATIENT PREPARATION ................................................................................................................................. 97 10.2. ANAESTHESIA AND PATIENT POSITIONING ................................................................................................... 97 10.3. PAIN MANAGEMENT .................................................................................................................................. 98 10.4. ANTI-INFECTIVE THERAPY ............................................................................................................................. 98 10.5. PROPHYLAXIS OF THROMBOSIS ...................................................................................................................... 99 10.6. PRE AND POSTOPERATIVE SUPPORTIVE CARE BY SPECIFIC TUMOUR SITES .................................................. 99 10.6.1. HEAD AND NECK CANCER ............................................................................................................................... 99 10.6.2. BREAST CANCER ........................................................................................................................................... 100 10.6.3. PROSTATE CANCER ........................................................................................................................................ 100 10.6.4. GYNAECOLOGICAL TUMOURS ........................................................................................................................ 101 10.7. FOLLOW-UP ............................................................................................................................................... 102 YY CERVICAL CANCER 103 11.1. INDICATIONS ............................................................................................................................................. 103 11.2. BRACHYTHERAPY PRE-PLANNING .............................................................................................................. 103 11.2.1. BRACHYTHERAPY TARGET VOLUMES ............................................................................................................... 103 11.2.2. ORGANS AT RISK .......................................................................................................................................... 105 11.2.3. DOSE OPTIMISATION .................................................................................................................................. 105 11.2.4. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................. 112 11.3. TECHNIQUE OF APPLICATOR INSERTION .....................................................................................................112 11.4. RESULTS ....................................................................................................................................................113 11.4.1. CONCOMITANT CHEMORADIOTHERAPY ........................................................................................................ 113 11.5. SIDE EFFECTS ............................................................................................................................................. 114 11.6. SUMMARY ................................................................................................................................................ 114 YY ENDOMETRIAL CARCINOMA 117 12.1. INDICATIONS, PATIENT SELECTION CRITERIA ................................................................................................ 117 12.1.1. CURRENT INDICATIONS FOR ADJUVANT RADIOTHERAPY, INCLUDING BRACHYTHERAPY ........................................ 117 12.1.1.1. LOW RISK ENDOMETRIAL CANCER ..................................................................................................................... 117 12.1.1.2. INTERMEDIATE RISK ENDOMETRIAL CANCER ....................................................................................................... 117 14 CONTENTS 12.1.1.3. HIGH TO INTERMEDIATE RISK ENDOMETRIAL CANCER .......................................................................................... 118 12.1.1.4. HIGH RISK ENDOMETRIAL CANCER .................................................................................................................... 118 12.1.1.5. ADJUVANT INTRAVAGINAL BRACHYTHERAPY ....................................................................................................... 119 12.1.2. BRACHYTHERAPY IN PRIMARY ENDOMETRIAL CARCINOMA ............................................................................... 119 12.1.3. INTRACAVITARY AND INTERSTITIAL BRACHYTHERAPY FOR RECURRENCES ............................................................... 119 12.2. TREATMENT PLANNING ............................................................................................................................. 120 12.2.1. TARGET VOLUMES ....................................................................................................................................... 120 12.2.1.1. ADJUVANT INTRACAVITARY BRACHYTHERAPY ....................................................................................................... 120 12.2.1.2. PRIMARY BRACHYTHERAPY .............................................................................................................................. 121 12.2.1.3. INTERSTITIAL BRACHYTHERAPY IN RECURRENT DISEASE .......................................................................................... 122 12.2.2. DOSE SPECIFICATION .................................................................................................................................... 122 1 2.2.2.1 . ADJUVANT BRACHYTHERAPY ............................................................................................................................. 122 1 2.2.2.2. PRIMARY BRACHYTHERAPY .............................................................................................................................. 123 1 2.2.2.3. INTERSTITIAL BRACHYTHERAPY ........................................................................................................................... 123 12.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................. 123 12.3. PRACTICAL EXECUTION AND TECHNIQUE ...................................................................................................... 124 12.3.1. ADJUVANT BRACHYTHERAPY .......................................................................................................................... 124 12.3.2. PRIMARY BRACHYTHERAPY ............................................................................................................................ 124 12.3.3. INTERSTITIAL BRACHYTHERAPY ........................................................................................................................ 124 12.4. RESULTS .....................................................................................................................................................125 12.5. SIDE EFFECTS .............................................................................................................................................. 125 12.6. SUMMARY .................................................................................................................................................. 126 YY PRIMARY VAGINAL CARCINOMA 128 13.1. INDICATIONS .............................................................................................................................................. 128 13.2. BRACHYTHERAPY PRE-PLANNING ............................................................................................................... 128 13.2.1. TARGET VOLUME ......................................................................................................................................... 128 13.2.2. ORGANS AT RISK ........................................................................................................................................... 130 13.2.3. DOSE PLANNING .......................................................................................................................................... 130 13.2.4. DOSE, DOSE RATE AND FRACTIONATION ........................................................................................................... 131 1 3.2.4.1 . PLANNING AIMS FOR THE TARGET VOLUMES ........................................................................................................ 131 1 3.2.4.2. DOSE CONSTRAINTS FOR THE ORGANS AT RISK ...................................................................................................... 132 13.3. PRACTICAL EXECUTION AND TECHNIQUE ...................................................................................................... 132 13.4. RESULTS ......................................................................................................................................................133 13.5. SIDE EFFECTS .............................................................................................................................................. 133 13.6. SUMMARY .................................................................................................................................................. 134 YY VULVAR CARCINOMA 135 14.1. INDICATIONS, PATIENT SELECTION CRITERIA ................................................................................................. 136 14.2. TREATMENT PLANNING .............................................................................................................................. 136 14.2.1. TARGET VOLUMES ........................................................................................................................................ 136 14.2.2. DOSE SPECIFICATION ..................................................................................................................................... 137 14.2.3. DOSE, DOSE RATE, FRACTIONATION .................................................................................................................. 138 14.3. PRACTICAL EXECUTION AND TECHNIQUE ...................................................................................................... 138 14.4. RESULTS ...................................................................................................................................................... 140 14.5. SIDE EFFECTS ............................................................................................................................................... 140 14.6. SUMMARY .................................................................................................................................................. 141 CONTENTS 15 B CARCINOMA OF THE FEMALE URETHRA 142 15.1. INDICATIONS, PATIENT SELECTION CRITERIA .................................................................................................142 15.2. TREATMENT PLANNING ............................................................................................................................ 142 15.2.1. TARGET VOLUMES ....................................................................................................................................... 142 15.2.2. DOSE SPECIFICATION ................................................................................................................................... 142 15.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................. 143 15.3. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 143 15.4. RESULTS .................................................................................................................................................... 144 15.5. SIDE EFFECTS ............................................................................................................................................. 144 15.6. SUMMARY ................................................................................................................................................ 145 YY CARCINOMA OF THE PROSTATE 146 16.1. INDICATIONS, PATIENT SELECTION CRITERIA ................................................................................................147 16.1.1. PERMANENT BRACHYTHERAPY WITH J-1 25 SEEDS ......................................................................................... 147 16.1.2. TEMPORARY BRACHYTHERAPY WITH IR 192 ................................................................................................... 147 16.1.3. CONTRAINDICATIONS TO BRACHYTHERAPY ..................................................................................................... 147 16.2. TREATMENT PLANNING ................................................ 147 16.2.1. TARGET VOLUMES AND ORGANS AT RISK ........................................................................................................ 147 16.2.2. ISOTOPE, DOSE SPECIFICATION AND FRACTIONATION ....................................................................................... 148 1 6.2.2.1 . PERMANENT BRACHYTHERAPY WITH J-1 25, PD-1 03 ......................................................................................... 148 16.2.2.2. TEMPORARY BRACHYTHERAPY WITH IR-192 ....................................................................................................... 148 16.3. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 149 16.3.1. PERMANENT BRACHYTHERAPY (SEEDS) ........................................................................................................ 150 16.3.2. TEMPORARY BRACHYTHERAPY ...................................................................................................................... 151 16.4. RESULTS ..................................................................................................................................................... 154 16.4.1. PERMANENT BRACHYTHERAPY (SEEDS) ........................................................................................................ 154 16.4.2. TEMPORARY BRACHYTHERAPY (HDR) .......................................................................................................... 154 16.4.3. SALVAGE BRACHYTHERAPY AS RE-IRRADIATION ............................................................................................... 155 16.5. SIDE EFFECTS .............................................................................................................................................155 16.5.1. PERMANENT BRACHYTHERAPY (SEEDS) ........................................................................................................ 155 16.5.2. TEMPORARY BRACHYTHERAPY (HDR) .......................................................................................................... 155 16.6. SUMMARY ................................................................................................................................................. 156 YY CARCINOMA OF THE PENIS 159 17.1. INDICATIONS, PATIENT SELECTION CRITERIA ................................................................................................ 159 17.2. TREATMENT PLANNING ............................................................................................................................. 159 17.3. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 159 17.3.1. SURFACE MOULD BRACHYTHERAPY ............................................................................................................... 159 17.3.2. INTERSTITIAL BRACHYTHERAPY ........................................................................................................................ 160 17.4. RESULTS .................................................................................................................................................... 163 17.5. SIDE EFFECTS ............................................................................................................................................. 163 17.5.1. EARLY SIDE EFFECTS ..................................................................................................................................... 163 17.5.2. LATE SIDE EFFECTS ....................................................................................................................................... 163 17.6. SUMMARY ................................................................................................................................................. 164 YY BLADDER CANCER 165 18.1. INDICATIONS ............................................................................................................................................. 165 18.2. TREATMENT PLANNING ............................................................................................................................ 165 16 CONTENTS 18.3. DOSE SPECIFICATION ................................................................................................................................. 166 18.4. DOSE, DOSE RATE AND FRACTIONATION ......................................................................................................167 18.5. PRACTICAL EXECUTION AND TECHNIQUE ................................................................................... 167 18.6. RESULTS ...................................................................................................................................................... 167 18.7. SIDE EFFECTS .............................................................................................................................................. 168 18.8. SUMMARY .................................................................................................................................................. 168 YY HEAD AND NECK TUMOURS 170 19.1. CARCINOMA OF THE LIP .............................................................................................................................. 170 19.1.1. INDICATIONS, PATIENT SELECTION CRITERIA ..................................................................................................... 170 19.1.2. TREATMENT PLANNING ................................................................................................................................. 170 19.1.2.1. TARGET VOLUMES .......................................................................................................................................... 170 19.1.2.2. DOSE SPECIFICATION ....................................................................................................................................... 170 19.1.2.3. DOSE, DOSE RATE, FRACTIONATION ..................................................................................................................... 172 19.1.3. PRACTICAL EXECUTION, TECHNIQUE ................................................................................................................ 172 19.1.4. RESULTS ........................................................................................................................................................ 172 19.1.5. SIDE EFFECTS ............................................................................................................................................... 172 19.2. ORAL CAVITY: CARCINOMA OF THE FLOOR OF THE MOUTH, CARCINOMA OF THE MOBILE TONGUE .............172 19.2.1. INDICATIONS, PATIENT SELECTION CRITERIA ..................................................................................................... 172 19.2.2. TREATMENT PLANNING ................................................................................................................................. 174 1 9.2.2.1 . TARGET VOLUMES ................................................... 174 1 9.2.2.2. DOSE SPECIFICATION ...................................................................................................................................... 175 19.2.23. DOSE, DOSE RATE, FRACTIONATION .................................................................................................................... 175 19.2.3. PRACTICAL EXECUTION, TECHNIQUE ............................................................................................................... 175 19.2.4. RESULTS ....................................................................................................................................................... 177 19.2.5. SIDE EFFECTS .............................................................................................................................................. 178 19.3. OROPHARYNX ............................................................................................................................................ 178 19.3.1. INDICATIONS, PATIENT SELECTION CRITERIA ..................................................................................................... 178 19.3.2. TREATMENT PLANNING ................................................................................................................................ 178 1 9.3.2.1 . TARGET VOLUMES .......................................................................................................... 178 193.2.2. DOSE SPECIFICATION ...................................................................................................................................... 178 19.3.23. DOSE, DOSE RATE, FRACTIONATION .................................................................................................................... 178 19.3.3. PRACTICAL EXECUTION, TECHNIQUE ............................................................................................................... 179 19.3.4. RESULTS ....................................................................................................................................................... 182 19.3.5. COMPLICATIONS ......................................................................................................................................... 182 19.4. BUCCAL MUCOSA ...................................................................................................................................... 182 19.4.1. INDICATIONS, PATIENT SELECTION CRITERIA ..................................................................................................... 182 19.4.2. TREATMENT PLANNING ................................................................................................................................ 182 1 9.4.2.1 . TARGET VOLUMES ......................................................................................................................................... 182 1 9.4.2.2. DOSE SPECIFICATION ...................................................................................................................................... 182 19.4.23. DOSE, DOSE RATE, FRACTIONATION .................................................................................................................... 182 19.4.3. PRACTICAL EXECUTION AND TECHNIQUE ................................................................................ 183 19.4.4. RESULTS ....................................................................................................................................................... 183 19.4.5. SIDE EFFECTS .............................................................................................................................................. 183 19.5. NASOPHARYNX ..........................................................................................................................................183 19.5.1. INDICATIONS, PATIENT SELECTION CRITERIA ..................................................................................................... 183 19.5.2. TREATMENT PLANNING ................................................................................................................................ 183 1 9.5.2.1 . TARGET VOLUMES ......................................................................................................................................... 183 1 9.5.2.2. DOSE SPECIFICATION ...................................................................................................................................... 183 19.5.23. DOSE, DOSE RATE, FRACTIONATION .................................................................................................................... 183 19.5.3. PRACTICAL EXECUTION, TECHNIQUE ............................................................................................................... 184 CONTENTS 17 19.5.4. RESULTS ...................................................................................................................................................... 184 19.5.5. SIDE EFFECTS .............................................................................................................................................. 186 19.6. NASAL CANCER ...........................................................................................................................................186 19.6.1. INDICATIONS, PATIENT SELECTION CRITERIA .................................................................................................... 186 19.6.2. TREATMENT PLANNING ................................................................................................................................ 186 1 9.6.2.1 . TARGET VOLUMES ........................................................................................................................................ 186 1 9.6.2.2. DOSE SPECIFICATION ..................................................................................................................................... 186 19.6.23. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................... 186 19.6.3. PRACTICAL EXECUTION, TECHNIQUE ............................................................................................................... 186 19.6.4. RESULTS...................................................................................................................................................... 188 19.6.5. SIDE EFFECTS .............................................................................................................................................. 188 19.7. SUMMARY ................................................................................................................................................ 188 YY BREAST CANCER 191 20.1. INDICATIONS, PATIENT SELECTION CRITERIA ............................................................................................... 191 20.1.1. INTERSTITIAL BRACHYTHERAPY AS BOOST ........................................................................................................ 191 20.1.2. PARTIAL BREAST IRRADIATION WITH INTERSTITIAL MULTICATHETER BRACHYTHERAPY ALONE .................................. 191 20.1.3. POSTOPERATIVE SURFACE/INTERSTITIAL BRACHYTHERAPY OF THE CHEST WALL AFTER CHEST WALL RECURRENCE IN PATIENTS WHO HAVE PREVIOUSLY HAD RADIOTHERAPY ................................................................ 193 20.2. TREATMENT PLANNING ............................................................................................................................ 193 20.2.1. TARGET VOLUMES ...................................................................................................................................... 193 20.2.1.1. INTERSTITIAL BRACHYTHERAPY .......................................................................................................................... 193 20.2.1.2. TARGET VOLUME IN SURFACE BRACHYTHERAPY ................................................................................................. 199 20.2.1.3. TARGET VOLUME IN INTERSTITIAL BRACHYTHERAPY FOR THE CHEST WALL ................................................................. 199 20.2.2. DOSE SPECIFICATION ................................................................................................................................... 199 20.2.2.1. INTERSTITIAL BRACHYTHERAPY .......................................................................................................................... 199 20.2.2.2. SURFACE BRACHYTHERAPY ............................................................................................................................. 200 20.2.2.3. INTERSTITIAL BRACHYTHERAPY CHEST WALL ........................................................................................................ 200 20.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................200 20.3. PRACTICAL EXECUTION AND TECHNIQUE .................................................................................................... 201 20.3.1. INTERSTITIAL BRACHYTHERAPY ....................................................................................................................... 201 20.3.2. MOULD (SURFACE BRACHYTHERAPY) ............................................................................................................ 204 20.3.3. INTERSTITIAL BRACHYTHERAPY OF THE CHEST WALL .......................................................................................... 204 20.4. RESULTS .................................................................................................................................................... 204 20.4.1. BOOST ....................................................................................................................................................... 204 20.4.2. INTERSTITIAL BRACHYTHERAPY ALONE ............................................................................................................ 205 20.4.3. SURFACE RADIOTHERAPY OF THE CHEST WALL AS RE-IRRADIATION ..................................................................... 205 20.5. SIDE EFFECTS ............................................................................................................................................ 205 20.5.1. BOOST .......................................................................................................................................................206 20.5.2. INTERSTITIAL BRACHYTHERAPY ALONE AS APBI ...............................................................................................206 20.5.3. SURFACE SALVAGE-BRACHYTHERAPY AS RE-IRRADIATION .................................................................................206 20.6. SUMMARY ................................................................................................................................................ 206 YY LUNG CANCER 210 21.1. INDICATIONS, PATIENT SELECTION CRITERIA ............................................................................................... 210 21.1.1. CURATIVE ENDOBRONCHIAL BRACHYTHERAPY ...............................................................................................210 21.1.2. PALLIATIVE ENDOBRONCHIAL BRACHYTHERAPY ............................................................................................... 211 21.1.3. CURATIVE ENDOBRONCHIAL BRACHYTHERAPY COMBINED WITH EXTERNAL BEAM RADIOTHERAPY ................... 211 21.1.4. PALLIATIVE ENDOBRONCHIAL BRACHYTHERAPY IN COMBINATION WITH EXTERNAL BEAM RADIOTHERAPY ............ 211 18 CONTENTS 21.2. TREATMENT PLANNING ............................................................................................................................. 212 21.2.1. TARGET VOLUMES .......................................................................................................................................212 21.2.1.1. THE TARGET VOLUME FOR A CURATIVE INTENTION ............................................................................................... 212 21.2.1.2. THE TARGET VOLUME FOR A PALLIATIVE INTENTION ............................................................................................. 212 21.2.2. DOSE SPECIFICATION ....................................................................................................................................212 21.2.2.1. THE DOSE SPECIFICATION FOR A CURATIVE INTENTION .......................................................................................... 212 21.2.2.2. THE DOSE SPECIFICATION FOR A PALLIATIVE INTENTION ........................................................................................ 213 21.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................. 213 21.3. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 214 21.4. RESULTS ..................................................................................................................................................... 215 21.4.1. RESULTS OF ENDOBRONCHIAL HDR OR LDR BRACHYTHERAPY ALONE IN CURATIVE INTENTION ......................... 215 21.4.2. RESULTS OF COMBINED EXTERNAL BEAM AND ENDOBRONCHIAL RADIOTHERAPY IN CURATIVE INTENTION .......... 215 21.4.3. RESULTS OF ENDOBRONCHIAL HDR OR LDR BRACHYTHERAPY ALONE IN PALLIATIVE INTENTION ........................ 215 21.4.4. RESULTS OF COMBINED EXTERNAL BEAM AND ENDOBRONCHIAL RADIOTHERAPY IN PALLIATIVE INTENTION .... 216 21.5. SIDE EFFECTS .............................................................................................................................................. 216 21.6. INTERSTITIAL AND INTRAOPERATIVE BRACHYTHERAPY - INDICATION, TECHNIQUE, RESULTS ......................... 218 21.7. SUMMARY .................................................................................................................................................. 219 YY OESOPHAGEAL CARCINOMA 222 22.1. INDICATIONS, PATIENT SELECTION ............................................................................................................... 222 22.2. TREATMENT PLANNING ......................................... 222 22.2.1. TARGET VOLUMES ................................................................................................ 222 22.2.2. DOSE SPECIFICATION .................................................................................................................................... 224 22.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................. 225 22.3. PRACTICAL EXECUTION AND TECHNIQUE ...................................................................................................... 225 22.4. RESULTS ..................................................................................................................................................... 226 22.5. SIDE EFFECTS .............................................................................................................................................. 227 22.6. SUMMARY .................................................................................................................................................. 228 YY CARCINOMA OF THE ANAL CANAL 230 23.1. INDICATIONS, PATIENT SELECTION CRITERIA ................................................................................................ 230 23.2. TREATMENT PLANNING ............................................................................................................................. 230 23.2.1. TARGET VOLUMES ....................................................................................................................................... 231 23.2.2. DOSE SPECIFICATION .................................................................................................................................... 231 23.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................. 231 23.3. PRACTICAL EXECUTION AND TECHNIQUE ...................................................................................................... 232 23.4. RESULTS AND SIDE EFFECTS ........................................................................................................................ 233 23.5. SIDE EFFECTS ....................................................................................................................................... 234 23.6. SUMMARY .................................................................................................................................................. 235 YY SKIN TUMOURS 237 24.1. INDICATIONS, PATIENT SELECTION CRITERIA ................................................................................................ 237 24.2. TREATMENT PLANNING ............................................................................................................................. 237 24.2.1. TARGET VOLUMES ........................................................................................................................................238 24.2.2. DOSE SPECIFICATION .....................................................................................................................................238 24.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................. 238 24.3. PRACTICAL EXECUTION AND TECHNIQUE ...................................................................................................... 238 24.4. RESULTS ...................................................................................................................................................... 241 CONTENTS 19 24.5. SIDE EFFECTS ............................................................................................................................. 242 24.6. SUMMARY ............................................................................................................................................... 242 B UVEAL CHOROIDAL MELANOMAS 244 25.1. INDICATIONS, PATIENT SELECTION CRITERIA ............................................................................................... 244 25.2. TREATMENT PLANNING ............................................................................................................................ 244 25.2.1. TARGET VOLUMES ...................................................................................................................................... 244 25.2.2. EYE PLAQUES .............................................................................................................................................245 25.2.2.1. RUTHENIUM-1 06 EYE PLAQUES ..................................................................................................................... 245 25.2.2.2. IODINE-1 25 EYE PLAQUES ............................................................................................................................. 245 25.2.3. DOSE SPECIFICATION AND DOSIMETRY .........................................................................................................246 25.2.3.1. RUTHENIUM-1 06 EYE PLAQUES ..................................................................................................................... 246 25.2.3.2. IODINE-1 25 EYE PLAQUES ............................................................................................................................. 247 25.3. PRACTICAL EXECUTION AND TECHNIQUE .................................................................................................... 247 25.4. RESULTS .................................................................................................................................................... 249 25.5. SIDE EFFECTS ............................................................................................................................................ 251 25.6. SUMMARY .................................................................... 251 YY PAEDIATRIC MALIGNANCIES 253 26.1. INDICATIONS ............................................................................................................................................. 253 26.2. TREATMENT PLANNING ............................................................................................................................ 253 26.2.1. TARGET VOLUMES ...................................................................................................................................... 253 26.2.2. DOSE SPECIFICATION ................................................................................................................................... 253 26.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................ 253 26.3. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 253 26.4. RESULTS .................................................................................................................................................... 255 26.5. SIDE EFFECTS ............................................................................................................................................. 256 26.6. SUMMARY ....................................................................................................................................... .....256 YY PRIMARY AND SECONDARY LIVER MALIGNANCIES 257 27.1. INDICATION, PATIENT SELECTION CRITERIA ................................................................................................. 257 27.2. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 257 27.3. TREATMENT PLANNING ............................................................................................................................ 259 27.4. RESULTS .................................................................................................................................................... 262 27.5. SUMMARY ................................................................................................................................................ 263 YY SOFT TISSUE SARCOMAS 266 28.1. INDICATIONS, PATIENT SELECTION CRITERIA ............................................................................................... 266 28.2. TREATMENT PLANNING ............................................................................................................................ 266 28.2.1. TARGET VOLUMES ......................................................................................................................................266 28.2.2. DOSE SPECIFICATION ...................................................................................................................................266 28.2.3. DOSE, DOSE RATE, FRACTIONATION ................................................................................................................ 266 28.3. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 266 28.4. RESULTS .................................................................................................................................................... 267 28.5. SIDE EFFECTS ............................................................................................................................................ 269 28.6. SUMMARY ................................................................................................................................................ 269 20 CONTENTS YY KELOIDS AND PTERYGIA 275 29.1. INDICATIONS, PATIENT SELECTION CRITERIA ................................................................................................. 275 29.2. TREATMENT PLANNING ............................................................................................................................. 275 29.2.1. TARGET VOLUMES ....................................................................................................................................... 275 29.2.2. DOSE SPECIFICATION .................................................................................................................................... 275 29.2.3. DOSE, DOSE RATE, FRACTIONATION .................................................................................................. 275 29.3. PRACTICAL EXECUTION AND TECHNIQUE ..................................................................................................... 276 29.4. RESULTS ..................................................................................................................................................... 278 29.5. SIDE EFFECTS .............................................................................................................................................. 278 29.6. SUMMARY ................................................................................................................................................. 279 YY PERSPECTIVES IN BRACHYTHERAPY 281 30.1. SUMMARY ................................................................................................................................................. 283 YY INDEX 284
any_adam_object	1
author	Strnad, Vratislav Niehoff, Peter 1967- Lößl, Kristina 1967- Kirisits, Christian
author2	Strnad, Vratislav Niehoff, Peter 1967- Lößl, Kristina 1967- Kirisits, Christian
author2_role	edt edt edt edt
author2_variant	v s vs p n pn k l kl c k ck
author_GND	(DE-588)1146611870 (DE-588)120743051 (DE-588)124526276
author_facet	Strnad, Vratislav Niehoff, Peter 1967- Lößl, Kristina 1967- Kirisits, Christian Strnad, Vratislav Niehoff, Peter 1967- Lößl, Kristina 1967- Kirisits, Christian
author_role	aut aut aut aut
author_sort	Strnad, Vratislav
author_variant	v s vs p n pn k l kl c k ck
building	Verbundindex
bvnumber	BV049092439
classification_rvk	YR 3303
ctrlnum	(OCoLC)1371482539 (DE-599)DNB1281984809
dewey-full	615.842
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	615 - Pharmacology and therapeutics
dewey-raw	615.842
dewey-search	615.842
dewey-sort	3615.842
dewey-tens	610 - Medicine and health
discipline	Medizin
edition	2nd edition
format	Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02217nam a2200541 c 4500</leader><controlfield tag="001">BV049092439</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20240215 </controlfield><controlfield tag="007">t\|</controlfield><controlfield tag="008">230807s2023 gw a\|\|\| \|\|\|\| 00\|\|\| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">23,N10</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">23,A19</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1281984809</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837416473</subfield><subfield code="c">Festeinband : EUR 69.80 (DE), EUR 71.80 (AT), CHF 74.80 (freier Preis)</subfield><subfield code="9">978-3-8374-1647-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">383741647X</subfield><subfield code="9">3-8374-1647-X</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783837416473</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1371482539</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1281984809</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-HB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-578</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">615.842</subfield><subfield code="2">23/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YR 3303</subfield><subfield code="0">(DE-625)154103:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WN 250.5.B7</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Practical handbook of brachytherapy</subfield><subfield code="c">Vratislav Strnad, Peter Niehoff, Kristina Lössl, Christian Kirisits ; in collaboration with Stefanie Corradini [und 20 weiteren]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2nd edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen ; London ; Boston</subfield><subfield code="b">UNI-MED Verlag AG</subfield><subfield code="c">[2023]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">286 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">25 cm, 678 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED SCIENCE</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Brachytherapie</subfield><subfield code="0">(DE-588)4219194-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Brachytherapie</subfield><subfield code="0">(DE-588)4219194-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strnad, Vratislav</subfield><subfield code="0">(DE-588)1146611870</subfield><subfield code="4">edt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niehoff, Peter</subfield><subfield code="d">1967-</subfield><subfield code="0">(DE-588)120743051</subfield><subfield code="4">edt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lößl, Kristina</subfield><subfield code="d">1967-</subfield><subfield code="0">(DE-588)124526276</subfield><subfield code="4">edt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kirisits, Christian</subfield><subfield code="4">edt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">UNI-MED Verlag AG</subfield><subfield code="0">(DE-588)1065561733</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="780" ind1="0" ind2="0"><subfield code="i">Vorangegangen ist</subfield><subfield code="z">9783837414493</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034354136&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="883" ind1="2" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">dnb</subfield><subfield code="d">20230504</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#dnb</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034354136</subfield></datafield></record></collection>
genre	(DE-588)4143413-4 Aufsatzsammlung gnd-content
genre_facet	Aufsatzsammlung
id	DE-604.BV049092439
illustrated	Illustrated
indexdate	2024-12-20T20:00:36Z
institution	BVB
institution_GND	(DE-588)1065561733
isbn	9783837416473 383741647X
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-034354136
oclc_num	1371482539
open_access_boolean
owner	DE-578 DE-355 DE-BY-UBR
owner_facet	DE-578 DE-355 DE-BY-UBR
physical	286 Seiten Illustrationen, Diagramme 25 cm, 678 g
publishDate	2023
publishDateSearch	2023
publishDateSort	2023
publisher	UNI-MED Verlag AG
record_format	marc
series2	UNI-MED SCIENCE
spellingShingle	Strnad, Vratislav Niehoff, Peter 1967- Lößl, Kristina 1967- Kirisits, Christian Practical handbook of brachytherapy Brachytherapie (DE-588)4219194-4 gnd
subject_GND	(DE-588)4219194-4 (DE-588)4143413-4
title	Practical handbook of brachytherapy
title_auth	Practical handbook of brachytherapy
title_exact_search	Practical handbook of brachytherapy
title_full	Practical handbook of brachytherapy Vratislav Strnad, Peter Niehoff, Kristina Lössl, Christian Kirisits ; in collaboration with Stefanie Corradini [und 20 weiteren]
title_fullStr	Practical handbook of brachytherapy Vratislav Strnad, Peter Niehoff, Kristina Lössl, Christian Kirisits ; in collaboration with Stefanie Corradini [und 20 weiteren]
title_full_unstemmed	Practical handbook of brachytherapy Vratislav Strnad, Peter Niehoff, Kristina Lössl, Christian Kirisits ; in collaboration with Stefanie Corradini [und 20 weiteren]
title_short	Practical handbook of brachytherapy
title_sort	practical handbook of brachytherapy
topic	Brachytherapie (DE-588)4219194-4 gnd
topic_facet	Brachytherapie Aufsatzsammlung
url	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034354136&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
work_keys_str_mv	AT strnadvratislav practicalhandbookofbrachytherapy AT niehoffpeter practicalhandbookofbrachytherapy AT loßlkristina practicalhandbookofbrachytherapy AT kirisitschristian practicalhandbookofbrachytherapy AT unimedverlagag practicalhandbookofbrachytherapy

Verfügbarkeit

‌

Inhaltsverzeichnis